-Data Presentations Highlight Continued
Advances in Research for Treating Blood Cancers-
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from
its ADCETRIS® (brentuximab vedotin) clinical development program at
the 24th Annual Congress of the European Hematology Association
(EHA) taking place June 13-16 in Amsterdam; and the International
Conference on Malignant Lymphoma (ICML) from June 18-22 in Lugano.
Updated analyses from clinical trials evaluating ADCETRIS in
combination with Opdivo® (nivolumab), as well as encore analyses
from the phase 3 ECHELON-1, ECHELON-2 and ALCANZA clinical trials,
will be highlighted in 12 presentations at EHA and ICML. ADCETRIS
is an antibody-drug conjugate (ADC) directed to CD30, a defining
marker of classical Hodgkin lymphoma (HL) and expressed on the
surface of several types of peripheral T-cell lymphomas. Opdivo is
a programmed death-1 (PD-1) immune checkpoint inhibitor that is
designed to harness the body’s own immune system to help restore
anti-tumor immune response. ADCETRIS and Opdivo are not approved in
combination for the treatment of relapsed or refractory primary
mediastinal large B-cell lymphoma (PMBL), HL, pediatric HL or for
other indications. ADCETRIS in combination with bendamustine is not
approved for HL.
“This year at the EHA and ICML meetings, key ADCETRIS data will
be featured that continue to support our goal of further expanding
our clinical development program beyond the six ADCETRIS approved
indications,” said Roger Dansey, M.D., Chief Medical Officer at
Seattle Genetics. “We are excited about several ADCETRIS-related
presentations including encore oral presentations from the
ECHELON-1 and ECHELON-2 phase 3 trials, as well as clinical
research updates on ADCETRIS combination treatment strategies.”
Details of oral and poster
presentations featured at EHA include:
Abstract Title: Frontline Brentuximab Vedotin with
Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma: 3-Year
Update of the ECHELON-1 Study (Abstract #S820)Oral
Presentation Date and Time: Saturday, June 15, 12:00-12:15 p.m.
CESTLocation: Hall 5
Abstract Title: Nivolumab and Brentuximab Vedotin-based,
Response-adapted Treatment in Primary Refractory and in Pediatric
Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in
Checkmate 744 (Abstract #S822)Oral Presentation Date and
Time: Saturday, June 15, 12:30-12:45 p.m. CESTLocation:
Hall 5
Abstract Title: The ECHELON-2 Trial: Results of a Randomized,
Double-blind Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP)
versus CHOP in Frontline Treatment of Patients with CD30+
Peripheral T-cell Lymphomas (Abstract #PS1070)Poster
Presentation Date and Time: Saturday, June 15, 5:30-7:00 p.m.
CESTLocation: Poster Area
Abstract Title: Nivolumab Combined with Brentuximab Vedotin
for Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma:
Efficacy and Safety Results from the Phase 2 Checkmate 436 Study
(Abstract #S1601)Oral Presentation Date and Time:
Sunday, June 16, 9:00-9:15 a.m. CESTLocation: Hall 5
Details of oral and poster
presentations featured at ICML include:
Abstract Title: Safety and Response after 2 Cycles of
Brentuximab Vedotin Substituting Vincristine in the OEPA/COPDAC
Regimen for High Risk Pediatric Hodgkin Lymphoma (HL) (Abstract
#025)Oral Presentation Date and Time: Wednesday, June
19, 5:25 p.m. CESTLocation: Cinema Corso
Abstract Title: Response-Adapted Treatment with Nivolumab and
Brentuximab Vedotin in Young Patients with Relapsed/Refractory
Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses
(Abstract #026)Oral Presentation Date and Time:
Wednesday, June 19, 5:35 p.m. CESTLocation: Cinema Corso
Abstract Title: Extended Follow-up a Phase 1 Study of
Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with
Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN
Research Group (E4412: Arms A-I) (Abstract #077)Oral
Presentation Date and Time: Thursday, June 20, 5:45 p.m.
CESTLocation: Cinema Corso
Abstract Title: Nivolumab Combined with Brentuximab Vedotin
for Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma:
Efficacy and Safety Results from the Phase 2 Checkmate 436 Study
(Abstract #108)Oral Presentation Date and Time: Friday,
June 21, 2:15 p.m. CESTLocation: Room B, Palazzo dei
Congressi
Abstract Title: Response to A+CHP by CD30 Expression in the
ECHELON-2 Trial (Abstract #228)Poster Presentation Date and
Time: Wednesday-Friday, June 19-21, 12:00-5:00 p.m., 9:00
a.m.-5:00 p.m. and 9:00 a.m.-6:30 p.m. respectively,
CESTLocation: Marquee Parco Ciani
Abstract Title: Exploratory Biomarker Analysis in the Phase 3
ECHELON-1 Study: Worse Outcome with ABVD in Patients with Elevated
Baseline Levels of sCD30 and TARC (Abstract #235)Poster
Presentation Date and Time: Wednesday-Friday, June 19-21,
12:00-5:00 p.m., 9:00 a.m.-5:00 p.m. and 9:00 a.m.-6:30 p.m.
respectively, CESTLocation: Marquee Parco Ciani
Abstract Title: Brentuximab Vedotin and Bendamustine is a
Feasible and Effective Drug Combination as First-line Treatment of
Hodgkin Lymphoma in the Elderly (HALO trial) (Abstract
#237)Poster Presentation Date and Time:
Wednesday-Friday, June 19-21, 12:00-5:00 p.m., 9:00 a.m.-5:00 p.m.
and 9:00 a.m.-6:30 p.m. respectively, CESTLocation: Marquee
Parco Ciani
Abstract Title: Final Data from the Phase 3 ALCANZA Study:
Brentuximab Vedotin (BV) vs Physician’s Choice (PC) in Patients
(pts) with CD30-positive (CD30+) Cutaneous T-cell Lymphoma (CTCL)
(Abstract #232)Poster Presentation Date and Time:
Wednesday-Friday, June 19-21, 12:00-5:00 p.m., 9:00 a.m.-5:00 p.m.
and 9:00 a.m.-6:30 p.m. respectively, CESTLocation: Marquee
Parco Ciani
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes
transformative therapies targeting cancer to make a meaningful
difference in people’s lives. ADCETRIS® (brentuximab vedotin)
utilizes the company’s industry-leading antibody-drug conjugate
(ADC) technology and is currently approved for the treatment of
multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company
has established a pipeline of novel targeted therapies at various
stages of clinical testing, including three in ongoing pivotal
trials for solid tumors. Enfortumab vedotin for metastatic
urothelial cancer and tisotumab vedotin for metastatic cervical
cancer utilize our proprietary ADC technology. Tucatinib, a small
molecule tyrosine kinase inhibitor, is in a pivotal trial for
HER2-positive metastatic breast cancer. In addition, we are
leveraging our expertise in empowered antibodies to build a
portfolio of proprietary immuno-oncology agents in clinical trials
targeting hematologic malignancies and solid tumors. The company is
headquartered in Bothell, Washington, and has a European office in
Switzerland. For more information on our robust pipeline, visit
www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the therapeutic
potential of ADCETRIS, including the combination of ADCETRIS with
OPDIVO or other agents, the potential expansion of the company’s
ADCETRIS clinical development program and the potential for
additional approved indications of ADCETRIS. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the difficulty and uncertainty of pharmaceutical
product development, including the risks that Seattle Genetics or
its collaborators may experience delays in planned clinical trial
initiations or otherwise experience failures or setbacks in
clinical development due to lack of efficacy, adverse events or
other factors. Seattle Genetics or its collaborators may also be
delayed or unsuccessful in regulatory submissions and in obtaining
regulatory approvals for a variety of reasons including the
difficulty and uncertainty of pharmaceutical product development,
negative or disappointing clinical trial results, unexpected
adverse events, adverse regulatory actions and the inherent
uncertainty associated with the regulatory approval process. More
information about the risks and uncertainties faced by Seattle
Genetics is contained under the caption “Risk Factors” included in
the company’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2019 filed with the Securities and Exchange
Commission. Seattle Genetics disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
SOURCE: Seattle Genetics, Inc.
Opdivo® is a registered trademark of Bristol-Myers Squibb
Company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190612005283/en/
Media:Monique Greer(425) 527-4641mgreer@seagen.com
Investors:Peggy Pinkston(425) 527-4160ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024